Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asthma severity categorization using a claims-based algorithm or pulmonary function testing.

The Journal of asthma : official journal of the Association for the Care of Asthma·2009
Same author

Economic burden of pneumonia in an employed population.

Archives of internal medicine·2001
Same author

Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma.

The Journal of asthma : official journal of the Association for the Care of Asthma·2001
Same author

Impact of noninvasive studies to distinguish volume overload from ARDS in acutely ill patients with pulmonary edema: analysis of the medical literature from 1966 to 1998.

Chest·2000
Same author

Medical and surgical treatment of parapneumonic effusions : an evidence-based guideline.

Chest·2000
Same author

Comparing inhaled corticosteroids.

Respiratory care·2000

Related Experiment Video

Updated: Jul 12, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Proventil HFA prevents exercise-induced bronchoconstriction in children.

G L Colice1, N M Klinger, B P Ekholm

  • 13M Pharmaceuticals, St. Paul, Minnesota 55144-1000, USA.

The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|December 28, 1999
PubMed
Summary

Short-acting inhaled beta2-agonists effectively prevent exercise-induced bronchoconstriction (EIB) in children. Hydrofluoroalkane-134a (HFA) albuterol demonstrated equal effectiveness to chlorofluorocarbon (CFC) albuterol and superior effectiveness compared to placebo in protecting against EIB.

More Related Videos

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

Auricular Acupressure as an Adjuvant Treatment for Wheezing in Stable Chronic Obstructive Pulmonary Disease
02:34

Auricular Acupressure as an Adjuvant Treatment for Wheezing in Stable Chronic Obstructive Pulmonary Disease

Published on: May 10, 2024

Related Experiment Videos

Last Updated: Jul 12, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

Auricular Acupressure as an Adjuvant Treatment for Wheezing in Stable Chronic Obstructive Pulmonary Disease
02:34

Auricular Acupressure as an Adjuvant Treatment for Wheezing in Stable Chronic Obstructive Pulmonary Disease

Published on: May 10, 2024

Area of Science:

  • Pediatric Pulmonology
  • Respiratory Medicine
  • Pharmacology

Background:

  • Exercise-induced bronchoconstriction (EIB) is a common condition in children with asthma.
  • Short-acting inhaled beta2-agonists are frequently used for EIB prevention.
  • Previous formulations used chlorofluorocarbons (CFCs), which are being phased out.

Purpose of the Study:

  • To compare the efficacy of hydrofluoroalkane-134a (HFA) albuterol with CFC albuterol formulations and placebo.
  • To evaluate the effectiveness of these treatments in preventing EIB in asthmatic children.

Main Methods:

  • A randomized, single-blind, placebo-controlled, four-period crossover study.
  • Involved 6-11 year old asthmatic children.
  • Administered HFA albuterol, two CFC albuterol products, or placebo 30 minutes before exercise challenge.
  • Monitored spirometry (FEV1) and vital signs post-exercise.

Main Results:

  • All active albuterol treatments (HFA and CFC) were significantly more effective than placebo in preventing EIB.
  • The protective effect against EIB was similar across all three active treatments.
  • Fewer patients experienced a significant fall in FEV1 (>20%) with active treatments compared to placebo.
  • No significant differences in heart rate, blood pressure, or ECG intervals were observed between active treatments.

Conclusions:

  • HFA albuterol is a safe and effective alternative to CFC albuterol for preventing EIB in children.
  • HFA albuterol provides significant protection against exercise-induced bronchoconstriction, comparable to older CFC formulations.
  • This study supports the use of HFA albuterol as a preferred option for EIB prevention in pediatric asthma management.